Vyne Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vyne Therapeutics
VYNE Stock  USD 0.57  0.01  1.79%   
Vyne Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vyne Therapeutics' valuation are provided below:
Gross Profit
524 K
Market Capitalization
19 M
Enterprise Value Revenue
10.0433
Revenue
524 K
Earnings Share
(0.79)
There are over one hundred nineteen available fundamental trend indicators for Vyne Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Vyne Therapeutics' current performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 17, 2026, Market Cap is expected to decline to about 9.4 M. The current year's Enterprise Value is expected to grow to about (24.4 M)

Vyne Therapeutics Total Revenue

428,355

Check Vyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vyne Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 25.5 M or Other Operating Expenses of 63.3 M, as well as many indicators such as Price To Sales Ratio of 226, Dividend Yield of 0.0 or PTB Ratio of 2.59. Vyne financial statements analysis is a perfect complement when working with Vyne Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Vyne Stock
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Vyne Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets81.2 M76.9 M65.6 M
Slightly volatile
Other Current Liabilities7.6 M13.8 M5.4 M
Slightly volatile
Total Current Liabilities11.5 M17 M8.1 M
Slightly volatile
Accounts Payable3.3 M3.1 M2.3 M
Slightly volatile
Cash35.2 M22.9 M35.1 M
Slightly volatile
Cash And Short Term Investments70.1 M70.7 M58.6 M
Slightly volatile
Common Stock Total Equity2.4 K4.6 K2.4 K
Slightly volatile
Common Stock Shares Outstanding51.4 M49 M9.6 M
Slightly volatile
Liabilities And Stockholders Equity81.2 M76.9 M65.6 M
Slightly volatile
Other Current Assets4 M3.4 M2.6 M
Slightly volatile
Total Liabilities12.7 M13.3 M41.7 M
Slightly volatile
Total Current Assets77.7 M74.1 M63.4 M
Slightly volatile
Common Stock1.1 K1.1 K88.1 K
Pretty Stable
Other Liabilities997.5 K884.4 K692.1 K
Slightly volatile
Net Tangible Assets48.6 M28.1 M79.1 M
Slightly volatile
Property Plant And Equipment Net225.1 K236.9 K281.2 K
Slightly volatile
Current Deferred Revenue19.1 M18.2 M8.4 M
Slightly volatile
Non Current Assets Total2.8 M2.2 M5.9 M
Slightly volatile
Other Assets1.9 M2.9 M1.3 M
Slightly volatile
Net Receivables5.3 M5.9 M4.5 M
Slightly volatile
Non Current Liabilities Other1.6 M1.5 M570 K
Slightly volatile
Short Term Debt84.6 K89.1 K587.8 K
Pretty Stable
Property Plant Equipment302.7 K318.6 K1.2 M
Pretty Stable
Net Working Capital53.1 M44.7 M60.1 M
Very volatile
Short and Long Term Debt Total84.6 K89.1 K2.5 M
Very volatile
Long Term Debt26.5 M29.9 M32.6 M
Slightly volatile
Good Will3.6 M4.1 M4.5 M
Slightly volatile

Vyne Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative25.5 M15.2 M16.6 M
Slightly volatile
Other Operating Expenses63.3 M50.8 M41.9 M
Slightly volatile
Research Development30.7 M35.6 M21.1 M
Slightly volatile
Interest Income3.7 M3.6 M1.8 M
Slightly volatile
Total Revenue428.4 K450.9 K2.7 M
Very volatile
Gross Profit428.4 K450.9 K2.5 M
Very volatile
Cost Of Revenue4.4 K4.6 K485.9 K
Very volatile

Vyne Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.4 M3.8 M3.5 M
Slightly volatile
Begin Period Cash Flow34.7 M35.3 M22.7 M
Slightly volatile
End Period Cash Flow35.3 M22.9 M35.2 M
Slightly volatile
Dividends Paid251.4 K264.6 K20 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio226327469
Slightly volatile
Days Sales Outstanding3.6 K3.4 K1.3 K
Slightly volatile
Stock Based Compensation To Revenue4.415.933.8243
Slightly volatile
Capex To Depreciation27.6426.3313.8415
Slightly volatile
Inventory Turnover0.150.170.1847
Slightly volatile
Days Of Inventory On Hand1.6 K1.7 K1.9 K
Slightly volatile
Payables Turnover0.150.260.1644
Slightly volatile
Sales General And Administrative To Revenue17.2423.717.2857
Slightly volatile
Research And Ddevelopement To Revenue58.3755.5930.9033
Slightly volatile
Capex To Revenue0.220.210.1021
Slightly volatile
Cash Per Share1.581.66155
Slightly volatile
Days Payables Outstanding2.9 K1.4 K2.9 K
Slightly volatile
Income Quality0.660.770.8368
Very volatile
Net Debt To EBITDA0.50.523.7343
Slightly volatile
Current Ratio4.755.024.6201
Slightly volatile
Receivables Turnover0.10.113.0139
Slightly volatile
Debt To Equity0.00210.00220.0617
Very volatile
Capex Per Share0.0030.00320.0812
Slightly volatile
Revenue Per Share0.01290.01354.7127
Very volatile
Interest Debt Per Share0.00250.00273.4278
Pretty Stable
Debt To Assets0.00160.00170.0279
Very volatile
Operating Cycle1.8 K3.4 K1.6 K
Slightly volatile
Days Of Payables Outstanding2.9 K1.4 K2.9 K
Slightly volatile
Long Term Debt To Capitalization0.380.420.4613
Slightly volatile
Total Debt To Capitalization0.00210.00220.0353
Very volatile
Debt Equity Ratio0.00210.00220.0617
Very volatile
Quick Ratio4.755.024.5992
Slightly volatile
Net Income Per E B T1.171.151.0153
Slightly volatile
Cash Ratio1.471.5521.6733
Slightly volatile
Days Of Inventory Outstanding1.6 K1.7 K1.9 K
Slightly volatile
Days Of Sales Outstanding3.6 K3.4 K1.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0214
Slightly volatile
Fixed Asset Turnover2.662.825.6632
Slightly volatile
Debt Ratio0.00160.00170.0279
Very volatile
Price Sales Ratio226327469
Slightly volatile
Asset Turnover0.00820.00860.0318
Very volatile
Gross Profit Margin0.460.840.4746
Slightly volatile

Vyne Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.4 M9.9 M220.8 M
Slightly volatile

Vyne Fundamental Market Drivers

Vyne Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vyne Therapeutics Financial Statements

Vyne Therapeutics stakeholders use historical fundamental indicators, such as Vyne Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vyne Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vyne Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vyne Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vyne Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue18.2 M19.1 M
Total Revenue450.9 K428.4 K
Cost Of Revenue4.6 K4.4 K
Stock Based Compensation To Revenue 5.93  4.41 
Sales General And Administrative To Revenue 23.70  17.24 
Research And Ddevelopement To Revenue 55.59  58.37 
Capex To Revenue 0.21  0.22 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(100.16)(105.17)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:
How To Invest In Vyne
Details
Is Vyne Stock a good investment?
Details
What is Vyne Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Vyne diversify its offerings? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Vyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.79)
Revenue Per Share
0.012
Quarterly Revenue Growth
0.397
Return On Assets
(0.42)
Return On Equity
(0.71)
Understanding Vyne Therapeutics requires distinguishing between market price and book value, where the latter reflects Vyne's accounting equity. The concept of intrinsic value - what Vyne Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Vyne Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vyne Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY